Daniel Nelson, MD
Ophthalmology · Baton Rouge, LANPI 1912298167
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Alcon at 41.2% of the total. 2025 is the largest year on record at $1,464, 2.1 times the $689 reported in 2019.
Across 194 payments — averaging $31.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Glaukos Corporation$790
- Amgen$434
- Dompe US, Inc.$305
- Biotissue Holdings Inc.$300
- AbbVie$225
- plus $1K from 19 others
What the payments were for
- Food & beverage$6,023100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 78 | $2,482 |
| Glaukos Corporation | 16 | $790 |
| Amgen(2 entities) | 18 | $434 |
| Dompe US, Inc. | 12 | $305 |
| Biotissue Holdings Inc. | 11 | $300 |
| AbbVie(2 entities) | 10 | $225 |
| Abbott | 5 | $180 |
| Oyster Point Pharma, Inc. | 7 | $142 |
| E.r. Squibb & Sons, L.L.C. | 1 | $142 |
| Tarsus Pharmaceuticals, Inc. | 6 | $130 |
| Rxsight Inc | 1 | $121 |
| Kala Pharmaceuticals, Inc. | 5 | $119 |
| Lantheus Medical Imaging, Inc. | 1 | $113 |
| Angiodynamics, Inc. | 1 | $69 |
| Eyevance Pharmaceuticals LLC | 4 | $67 |
| Novartis | 4 | $66 |
| Biosense Webster, Inc. | 1 | $60 |
| Aerie Pharmaceuticals, Inc. | 3 | $59 |
| Sun Pharmaceutical Industries Inc. | 2 | $47 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $42 |
| Bausch & Lomb Americas Inc. | 2 | $39 |
| Boston Scientific | 1 | $33 |
| Harrow Eye, LLC | 1 | $23 |
| Shire North American Group Inc | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Photrexa Viscous and Photrexa$523
- Clareon$398
- LenSx$271
- TEPEZZA$258
- ELIQUIS$142
- ReSTOR$139
- AcrySof IQ PanOptix$133
- Hydrus Microstent$123
- RXSIGHT CONTACT LENS$121
- RXSIGHT INJECTOR CARTRIDGE$121
- RXSIGHT INJECTOR HANDPIECE$121
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$121
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$121
- HeartMate 3 Left Ventricular Assist Device$118
- Definity$113
How this compares
$6,023 in reported general payments places this provider in the 80th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 11 | $310,511 |
| RestasisCyclosporine | 128 | $128,712 |
| XiidraLifitegrast | 69 | $81,202 |
| CombiganBrimonidine Tartrate/Timolol | 73 | $24,218 |
| Loteprednol Etabonate | 144 | $24,098 |
| Prednisolone Acetate | 405 | $17,911 |
| TyrvayaVarenicline Tartrate | 25 | $15,861 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $11,610 |
| LumiganBimatoprost | 29 | $10,791 |
| Cyclosporine | 17 | $9,110 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 40 | $8,447 |
| Lotemax SmLoteprednol Etabonate | 28 | $7,710 |
| VyzultaLatanoprostene Bunod | 25 | $6,932 |
| IlevroNepafenac | 19 | $6,925 |
| Travoprost | 38 | $6,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $305 | $310,51111 claims |
| AbbVieRestasis, Combigan, Lumigan | $225 | $163,721230 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $39 | $88,13394 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Prolensa | $42 | $37,286188 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $142 | $15,86125 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $59 | $11,61030 claims |
| NovartisIlevro | $66 | $6,92519 claims |
| AlconSimbrinza | $2,482 | $5,04225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Baton Rouge
- Blake WilliamsonBaton Rouge$443K
- Charles WilliamsonBaton Rouge$16K
- David FargasonBaton Rouge$6K
- Philip EhrlichBaton Rouge$6K
- Michael MorganBaton Rouge$6K
- Thomas StuckeyBaton Rouge$6K
- George FivgasBaton Rouge$6K
- Devin TranBaton Rouge$5K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.